Which decisions define a laboratory sampling plan for peptide batch testing?
A laboratory sampling plan for peptide batch testing is a written rule that turns a physical lot into analytical decisions. It names the lot boundary, the sampling unit, the number of units, the selection method, the tests on each unit, and the accept or hold criterion. Without those elements, a purity percentage describes an aliquot, not the batch.
The lot boundary comes first. A synthesis crude, a purified bulk, a lyophilised fill from one cycle, and a packaged catalogue lot are different populations. The sampling unit is the item that can be selected: a vial, or a defined mass from a homogenised bulk. Increments scraped from the top of an unmixed powder are not a random sample of that bulk, however precise the balance.
Selection method is as important as sample size. Simple random selection, stratification by fill position or lyophiliser shelf, and systematic selection along a filling sequence answer different questions. Always testing the first vials filled estimates start-up conditions, not the lot. The plan should state whether strata are reported separately or pooled.
The decision rule is part of the plan. Attribute rules count nonconforming units against an acceptance number. Variables rules compare a mean, or a mean and a standard deviation, with a specification limit. The rule must also say what happens if a result is invalid: retest from a retain, repeat the preparation, or hold the lot. Repeating a chromatographic run until a passing trace appears is biased data selection, not sampling.
The plan should state the claim it can support. One vial tested once can show that the tested unit met an identity and purity specification under a named method. It cannot estimate within-lot standard deviation. Lot-level wording on a certificate should match that design limit.
How do consumer's risk and destructive tests fix the acceptance number?
Sampling plans can be constructed so that the probability of accepting poor quality, the consumer's risk, remains low at a chosen limiting quality (DOI:10.1520/jte11556j). That is a different objective from protecting the producer against rejection of an acceptable lot. A laboratory releasing research material, and a buyer checking a received lot, should both know which risk the integers n and c were built to control.
Identity confirmation and chromatographic purity are usually destructive. The aliquot is dissolved and consumed by the assay and cannot be returned as the same unit. Speevak and co-authors examined multiple-attribute acceptance plans in which testing destroys the unit, so each sampled item supports only one inspection path (DOI:10.2307/1269888). Peptide lots often need mass-spectrometric identity, reversed-phase HPLC purity, moisture and appearance from a small fill. The plan should assign units to tests before work starts. Taking extra vials after a questionable peak appears changes the plan after the data are seen.
Attributes do not substitute for one another. A unit may meet a purity threshold and fail identity, or the reverse. Accepting the lot when any one test passes is not the same rule as requiring every critical attribute to meet its limit. Where vials are scarce, the plan should say which non-destructive checks occur before a destructive aliquot is taken, and which attribute may consume the last retain.
Plans indexed only by n and c are incomplete. The record needs the acceptance quality limit and the lot tolerance fraction nonconforming those integers were chosen for, or the operating-characteristic curve cannot be read. When lot size N is small relative to n, sampling without replacement is the correct probability model. Switching to tightened inspection after a failure must be predefined. An unplanned extra pair of units inflates the chance of eventual acceptance.
How should compositional purity fractions be modelled in the plan?
Chromatographic purity and related-substance results are compositional. Area percentages in a peak table move toward a closed total, apart from rounding and excluded peaks. Treating each percentage as an independent normal variable is a modelling error near zero or 100 percent, because a normal distribution places probability outside the unit interval.
Govindaraju and co-authors set out sampling plans for compositional fractions that follow a beta distribution (DOI:10.1016/j.chemolab.2015.12.009). Support on the unit interval matches a reported fraction, and the two shape parameters can represent mean level and dispersion across sampling units. The plan must name the fraction under control: main-peak area percent, or the sum of related substances above the reporting threshold. A plan for main-peak purity cannot automatically control a specified impurity that can move while the main peak stays inside its limit.
Sample-size formulae copied from an unbounded variables plan can understate n when the mean sits near the specification and unit-to-unit dispersion is wide. Dispersion for that calculation comes from historical lots of the same sequence and process, not from replicate chromatographic runs of one preparation. Repeatability of the chromatographic run characterises the method. Between-vial dispersion characterises the lot. If historical dispersion is unknown, the honest record is a wider plan, or an explicit statement that lot-level variance was not estimated. Borrowing a system-suitability relative standard deviation answers a different question.
The fraction also depends on the integration rule. Excluding residual solvent, artefacts and peaks below the reporting threshold changes the denominator. Two laboratories can therefore report different fractions for the same physical lot for arithmetic reasons. The sampling plan should cite the wavelength, the reporting threshold and the handling of unidentified peaks that define the beta mean printed on the certificate. Without that definition, a beta sampling plan controls an unnamed quantity, and two certificates can look concordant while the denominators differ.
What should change for a short run when the analytical test is imperfect?
Many research peptide lots are short: one purification, or a lyophilised fill of tens of vials, not a long stable stream. Plans that assume large N and a continuous process do not describe that lot. Continuous sampling plans alternate between inspecting every unit and inspecting a fraction of units. Rodriguez and co-authors examined those plans in short-run contexts and under imperfect testing (DOI:10.3390/a11040046). Imperfect testing means a conforming unit can be recorded as nonconforming, or the reverse.
If the method's false-acceptance probability has not been characterised, increasing n while leaving the method unchanged may not deliver the consumer's risk written on the plan. Specificity evidence, peak-purity checks and an orthogonal mass measurement reduce misclassification. They are prerequisites for interpreting the sampling risk, not substitutes for taking more than one unit when the claim is about the lot.
Cost is a design constraint only when both sides are named. Kobilinsky and co-authors framed acceptance sampling as a minimum-cost problem, balancing the cost of increments against the cost of decision errors, in a grain-control application (DOI:10.1016/j.chemolab.2004.07.005). That arithmetic is not a peptide method and should not be copied as if a grain increment were a vial. The transferable point is that an optimum exists only after the cost of a false accept and the cost of a false reject are stated. Otherwise the laboratory can say that n was chosen, not that it was economical.
For very small N, testing every unit can be the clearer plan. One hundred percent inspection still needs a definition. Every vial weighed and inspected is not every vial chromatographed. If the n required by the target risks exceeds N, the compliant record widens the stated uncertainty or withholds a lot-level conformance claim. Reducing n because few vials remain will not preserve the operating characteristic.
Why can sampling variance outweigh method precision on the certificate?
Tittlemier and co-authors showed that sampling plans in current use can introduce high variance into mycotoxin test results, illustrated with an online FAO sampling tool (DOI:10.3920/wmj2022.2804). Grain contamination is not a model of peptide synthesis. The statistical caution still holds when an impurity or a constituent is unevenly distributed: which increments were taken can dominate the variance of the reported result, ahead of the repeatability of the determinative method. Quoting only chromatographic repeatability, or only a calibration-curve relative standard deviation, will not state the uncertainty of a lot-level peptide result.
Unevenness in a lyophilised peptide has ordinary physical sources. Incomplete mixing before filling, shelf-to-shelf differences in cake density, moisture gradients and segregation of a finer fraction can make two vials from one labelled lot analytically different. They become visible only if the plan samples more than one container or position and reports the spread.
A nested design separates the contributions. The lot contains containers or fill positions; a container contains the analytical preparation; the preparation contains replicate chromatographic runs. If between-vial variance is large, a second chromatographic run of the same vial barely tightens a lot estimate. The plan should state which level it is powered to estimate. A method-precision check should not be captioned as lot-uniformity evidence.
A 1991 discussion of central laboratory sampling plans described them as a quality-control design problem in a clinical-trial laboratory (DOI:10.1016/0197-2456(91)90039-o). A rule that exists only in an analyst's memory will not be applied the same way on the next lot. The batch record should store the plan revision, N, n, the selection method, container identifiers, exclusions made before testing, the preparation and data-file identifiers, and unit-level results rather than an average alone. Retains and any permitted retest should be defined in advance. A plain statement of how many units were selected, which tests consumed them, and whether within-lot dispersion was estimated lets a later reviewer match the certificate to the design.
Frequently asked questions
Is one tested vial a laboratory sampling plan for peptide batch testing?
It is a plan only if the lot boundary, the selection rule and the accept or hold criterion are written down. One vial can support a statement about that vial under a named method. It cannot estimate within-lot dispersion. If the certificate uses lot-level wording, the record should show how many units were selected and whether between-unit spread was measured. Otherwise the reader should read the figure as a unit result.
What is consumer's risk on a research peptide lot?
Consumer's risk is the probability of accepting a lot that sits at a chosen poor quality level, sometimes called the limiting quality or lot tolerance fraction nonconforming. Plans can be built so that this probability stays low (DOI:10.1520/jte11556j). The integers n and c do not state that risk by themselves. The record should also keep the quality levels those integers were selected to control, and whether sampling without replacement was assumed because testing consumes the unit.
Why is a normal distribution a poor model for chromatographic purity?
Area percent is a compositional fraction on a closed scale. Values cannot fall below zero or rise above 100 percent, yet a normal model assigns probability outside that interval, especially when the mean is near a specification at either end. Sampling plans for beta-distributed compositional fractions match the bounded support (DOI:10.1016/j.chemolab.2015.12.009). The plan still has to define the fraction, including wavelength, reporting threshold and peaks left out of the denominator.
When is testing every vial still an incomplete sampling plan?
Inspecting every unit is still a plan: n equals N, and the record should say so. It must also say whether every unit was weighed and examined visually, or whether every unit was chromatographed. Those designs estimate different quality characteristics. If the assay consumes the unit, 100 percent chromatographic testing consumes the lot. Visual inspection of every vial will not estimate a purity fraction.
Which records let a reviewer reconstruct the sampling plan?
Store the plan revision, lot identifier, lot size N, sample size n, selection method, container identifiers and any exclusion made before results were known. Cross-reference each tested unit to its preparation and data-file identifier, and keep unit-level results if more than one unit was tested. Define retains and any permitted retest before a failure occurs. A later average that hides a failing unit is not a reconstructable decision rule.
References
- DOI:10.1520/jte11556j — Sampling Plans with Low Consumers' Risk — Journal of Testing and Evaluation — 1981
- DOI:10.2307/1269888 — Multiple Attributes Sampling Acceptance Plans Involving Destructive Testing — Technometrics — 1987
- DOI:10.1016/j.chemolab.2015.12.009 — Sampling plans for beta distributed compositional fractions — Chemometrics and Intelligent Laboratory Systems — 2016
- DOI:10.3390/a11040046 — Short-Run Contexts and Imperfect Testing for Continuous Sampling Plans — Algorithms — 2018
- DOI:10.1016/j.chemolab.2004.07.005 — Minimum cost acceptance sampling plans for grain control, with application to GMO detection — Chemometrics and Intelligent Laboratory Systems — 2005
- DOI:10.3920/wmj2022.2804 — Current sampling plans can introduce high variance in mycotoxin testing results as demonstrated by the online FAO Mycotoxin Sampling Tool — World Mycotoxin Journal — 2023
- DOI:10.1016/0197-2456(91)90039-o — Central laboratory sampling plans and quality control in clinical trials — Controlled Clinical Trials — 1991
Research use only
This article is provided for laboratory research and educational purposes only. Products referenced are not for human or veterinary use. ClaraScience makes no therapeutic, medical, or efficacy claims, and nothing here constitutes medical advice.
